Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28040656 | 0.98 | KIF11 (0.69) | KIF11 | |
| SCHEMBL25400195 | 0.98 | KIF11 (0.74) | KIF11 | |
| SCHEMBL19371248 | 0.92 | KIF11 (0.77) | KIF11 | |
| SCHEMBL10330776 | 0.84 | KIF11 (0.61) | KIF11 | |
| SCHEMBL38315 | 0.84 | KIF11 (1.00) | KIF11 | |
| Hydrochloric Acid SCHEMBL34901 | 0.82 | KIF11 (0.96) | KIF11 | |
| SCHEMBL1995372 | 0.81 | KIF11 (0.56) | KIF11 | |
| SCHEMBL5350718 | 0.81 | KIF11 (0.55) | KIF11 | |
| SCHEMBL7796199 | 0.81 | KIF11 (0.55) | KIF11 | |
| SCHEMBL21093254 | 0.81 | KIF11 (0.55) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-12274737-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2025-04-15 | — | — | US | disclosed |
| EP-3193941-B1 | PRODRUGS COMPRISING AN AMINOALKYL GLYCINE LINKER | ASCENDIS PHARMA AS (DK) | 2024-05-22 | — | — | EP | disclosed |
| US-11633487-B2 | Prodrugs comprising an aminoalkyl glycine linker | ASCENDIS PHARMA A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-3922267-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-12-15 | — | — | EP | disclosed |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-07-22 | — | — | US | disclosed |
| EP-3050576-B1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S (DK) | 2021-03-31 | — | — | EP | disclosed |
| EP-0742790-A4 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0804456-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5681941-A | GENETIC ENGINEERING; CROSSLINKING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5578718-A | Thiol-derivatized nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0742790-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0716604-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995006474-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274737-B2 | PEGylated recombinant human growth hormone compounds | GHRHR, GHITM, GHSR | KIF11 1716/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | KIF11 3432/4885 |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | KIF11 1716/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | KIF11 3432/4885 |
| US-11633487-B2 | Prodrugs comprising an aminoalkyl glycine linker | DNPEP, PEPD, APEH | KIF11 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.